Mercury Systems, Inc. — Q3 FY2024 Form 10-Q
Reporting period: Third quarter and first nine months of fiscal 2024, ended March 29, 2024. The comparable periods ended March 31, 2023. Amounts below are in U.S. dollars; financial statement amounts are converted to millions unless noted.
Business context
Mercury supplies mission-critical processing products and systems for aerospace and defense programs. Management said it is prioritizing execution and completion of challenged programs and adjusting its operating cadence to better align material purchases with contract awards and available resources. Revenue can vary with customer delivery timing, and quarterly order patterns may not indicate future trends.
Financial performance
| Metric | Q3 FY2024 | Q3 FY2023 | Nine months FY2024 | Nine months FY2023 |
|---|---|---|---|---|
| Revenue | $208.3m | $263.5m | $586.7m | $720.6m |
| Gross margin | $40.6m (19.5%) | $90.3m (34.3%) | $122.7m (20.9%) | $249.3m (34.6%) |
| Operating income (loss) | $(45.7)m | $2.0m | $(139.8)m | $(12.8)m |
| Net income (loss) | $(44.6)m | $5.2m | $(126.9)m | $(20.1)m |
| Diluted EPS | $(0.77) | $0.09 | $(2.20) | $(0.36) |
| Adjusted EBITDA (non-GAAP) | $(2.4)m | $43.5m | $(21.7)m | $110.3m |
| Free cash flow (non-GAAP) | Not stated here | Not stated here | $(35.3)m | $(63.8)m |
Revenue fell 20.9% in the quarter and 18.6% for the nine-month period. Quarterly revenue declines were concentrated in integrated subsystems, radar, C4I, and land, airborne, and naval platforms; increases in other sensor and effector applications partly offset declines. For the nine months, revenue decreased across all product groupings, with the largest application declines in radar, electronic warfare, and C4I.
Gross margin contracted sharply. Management cited program cost growth, inventory reserves and scrap, and higher warranty expense. The quarter included $11.1m of inventory reserves and scrap and $4.9m of incremental warranty expense. Changes in program estimates reduced operating results by $16.0m in the quarter and $64.0m for the nine months. For the nine months, management reported approximately $63.9m of net program cost growth, including $25.8m attributable to challenged programs.
Cash, debt, and liquidity
- Cash and cash equivalents were $142.6m at March 29, 2024, up from $71.6m at June 30, 2023.
- Nine-month operating cash flow was $(11.4)m; investing cash flow was $(23.9)m and financing cash flow was $106.2m. Financing included $105.0m of Revolver borrowings. Free cash flow, a non-GAAP measure, was $(35.3)m.
- Long-term debt was $616.5m. The Revolver matures February 28, 2027. Under a temporary capacity reduction, gross capacity was approximately $750m at March 29, leaving about $133.5m before letters of credit. After the stated capacity-reset trigger, gross capacity was expected to rise to approximately $1,069.8m, subject to outstanding borrowings and other terms.
- The company reported compliance with Revolver covenants at quarter-end and expected to remain compliant for the rest of fiscal 2024. Management said available cash, operating cash flow, the Revolver, and financing capabilities should meet anticipated requirements for at least 12 months.
- Working-capital balances remain significant: unbilled receivables and costs in excess of billings were $325.4m and inventory was $343.0m. The company reported $44.2m of factored receivables at quarter-end under an uncommitted arrangement.
Material changes, outlook, and risks
- Restructuring charges were $9.8m in the quarter and $19.4m for the nine months. Workforce reductions eliminated approximately 100 positions in January 2024 and approximately 150 in August 2023, alongside other cost-saving actions. Remaining restructuring obligations are expected to be paid within 12 months.
- Management said cost growth on challenged programs had reduced significantly as it worked to retire risk and close out programs, and expected the revenue and operating-cadence trends described in the filing to continue through the remainder of fiscal 2024. The filing provides no quantitative full-year revenue or earnings guidance.
- Remaining performance obligations were $793.5m, with approximately 53% expected to be recognized as revenue in the next 12 months. These obligations exclude certain short-duration or cancellable orders.
- Goodwill was $938.1m and intangible assets were $261.8m. A market-capitalization decline triggered an interim Mission Systems goodwill test; estimated fair value exceeded carrying value by only 2.5%. Management said a 1.0 percentage-point increase in the discount rate would materially affect the valuation, and adverse operating trends could lead to impairment.
- Contingencies include a former CEO arbitration, with a potential exposure estimated at $0–$12.9m plus fees and compensation; a securities class action; California wage-and-hour and PAGA actions; and an environmental demand relating to a former site. The company disputes the claims; some matters are too early to estimate reliably. Non-cancelable purchase commitments totaled $138.6m, due within one year.
- Key disclosed risks include defense funding and government continuing resolutions, program execution and fixed-price cost growth, supply-chain and manufacturing issues, interest rates, litigation, and potential impairment of goodwill and intangible assets.
Important facts for investors to verify
- Whether challenged-program execution, cost estimates, scrap, and warranty costs improve, and whether reported margin recovery follows.
- Whether revenue timing and working-capital balances convert as management expects; monitor unbilled receivables, inventory, customer advances, and operating cash flow.
- The Revolver’s post-trigger capacity, covenant headroom, borrowing costs, and compliance as results evolve.
- Assumptions underlying the Mission Systems valuation and the risk of future goodwill impairment.
- Developments and potential financial exposure in the former CEO arbitration and other legal matters.
- Reconcile non-GAAP adjusted EBITDA, adjusted EPS, and free cash flow with GAAP results; the company notes these measures may not be comparable to similarly titled measures at other issuers.